FDA Fast Tracks PI-88 to Treat Postresection Liver Cancer

Publication
Article
OncologyONCOLOGY Vol 21 No 11
Volume 21
Issue 11

Progen Pharmaceuticals Limited announced that its investigational anticancer drug PI-88 has been awarded fast track status by the US Food and Drug Administration (FDA)

Progen Pharmaceuticals Limited announced that its investigational anticancer drug PI-88 has been awarded fast track status by the US Food and Drug Administration (FDA). The fast track designation has been granted to PI- 88 for the prevention of tumor recurrence following curative liver resection in patients with hepatocellular carcinoma (HCC, primary liver cancer).

Under the FDA Modernization Act of 1997, the fast track program is designed to facilitate the development and expedite the regulatory review of new drugs that demonstrate the potential to treat serious or life-threatening diseases where there is an unmet medical need. The fast track designation will enable Progen to file a new drug application (NDA) on a rolling basis as data becomes available. This permits the FDA to review the different components of the Drug Master File as they are completed in advance of receiving the final submission.

Unmet Need

Justus Homburg, Progen's CEO commented, "This designation will speed the process of bringing this potentially clinically very important drug to patients with liver cancer. The FDA decision to award fast track status to PI-88 was based on recent phase II clinical data and the high unmet need for treatments for patients with resectable primary liver cancer. The key phase II study showed that PI-88 has the potential to improve the time a patient remains disease-free following surgery. As we enter the final stages of clinical development and commence a multinational phase III trial, we look forward to collaborating closely with the FDA to expedite the development and approval of PI-88."

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content